文献速递炎症性肠病

乌司奴单抗治疗肛瘘型克罗恩病:GETAID随机安慰剂对照试验

Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID.
PubMed 文献 · Gut · 2026-07-24

该双盲多中心随机对照试验纳入32例活动性肛瘘型克罗恩病患者,评估乌司奴单抗与安慰剂在标准外科处理后的疗效与安全性。第12周联合缓解率乌司奴单抗组为62%、安慰剂组为25%(OR=5.1,95%CI 1.07-24.4),提示短期临床获益更优。

要点

  • 乌司奴单抗组第12周联合缓解率62%,安慰剂组25%,OR=5.1(95%CI 1.07-24.4)。
  • 临床缓解率62.5% vs 31%(OR=3.75,95%CI 0.84-16.8),影像学缓解率87.5% vs 75%。
  • 69%患者既往抗TNF治疗失败,提示乌司奴单抗在此类难治人群中仍有效。

核心结论

  • 乌司奴单抗较安慰剂在活动性肛瘘型肛周克罗恩病患者中显示更好的短期临床获益,支持其用于该类患者。

研究设计与样本

  • GETAID开展的双盲、多中心、随机安慰剂对照试验,共纳入32例活动性肛瘘型肛周克罗恩病患者,按1:1随机接受乌司奴单抗或安慰剂,均先接受标准化外科处理。

主要发现

  • 第12周联合缓解率乌司奴单抗组62%、安慰剂组25%,OR=5.1(95%CI 1.07-24.4)。
  • 第12周临床缓解率乌司奴单抗组62.5%、安慰剂组31%,OR=3.75(95%CI 0.84-16.8)。
  • 第12周影像学缓解率乌司奴单抗组87.5%、安慰剂组75%,OR=2.7(95%CI 0.34-21.1)。
  • 开放标签阶段9例安慰剂患者转为乌司奴单抗治疗。
  • 第48周联合缓解率安慰剂组50%、乌司奴单抗组31%。

关键数值与推荐

  • 主要终点为第12周联合临床缓解(所有外瘘口无引流)和影像学缓解(盲法中心MRI无大于2cm脓肿)。
  • 乌司奴单抗给药方案:基线6mg/kg静脉输注,第8周90mg皮下注射,此后每8周一次。

临床怎么用

  • 对于活动性肛瘘型肛周克罗恩病患者,尤其是抗TNF治疗失败者,可考虑乌司奴单抗联合标准化外科处理以争取短期联合缓解。

局限性

  • 样本量小(共32例),第12周临床缓解和影像学缓解的95%CI均较宽且跨越无效线。
  • 第48周联合缓解率安慰剂组高于乌司奴单抗组,长期获益不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fistulising perianal Crohn's disease (CD) remains a debilitating condition, with few randomised controlled trials conducted so far. OBJECTIVE: To evaluate the efficacy and safety of ustekinumab (UST) in patients with CD with active draining perianal fistulas (NCT04496063) in a randomised placebo-controlled trial. DESIGN: In this double-blind, multicentre Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives trial, patients enrolled with active fistulising perianal CD were randomised 1:1 to receive UST (6 mg/kg intravenously at baseline followed by 90 mg subcutaneously at week 8, then every 8 weeks) or placebo, after standardised surgical management. The primary endpoint was combined clinical remission (absence of drainage from all external fistula openings) and radiological remission (absence of abscesses >2 cm on blinded central MRI) at week 12. At week 12, placebo non-responders could switch to UST, and UST non-responders could be intensified during the open-label phase. RESULTS: 32 patients were randomised (UST: 16; placebo: 16) across 10 French centres and 69% had prior anti-tumour necrosis factor failure. At week 12, combined remission was achieved in 62% with UST versus 25% with placebo (OR=5.1 (95% CI 1.07-24.4)). Clinical remission occurred in 62.5% vs 31% (OR=3.75 (95% CI 0.84 to 16.8)) and radiological remission in 87.5% vs 75% (OR=2.7 (95% CI 0.34 to 21.1)). Nine placebo-patients switched to UST during the open-label phase. Combined remission rates at week 48 were 50% in the placebo arm and 31% in the UST arm, respectively. CONCLUSION: These findings suggest greater short-term clinical benefit with UST compared with placebo and support its use in patients with active fistulising perianal CD. TRIAL REGISTRATION NUMBER: NCT04496063.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wils P, Nancey S, Messmer E, et al. Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID. Gut. 2026. PMID: 42498622. doi:10.1136/gutjnl-2026-339158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。